

Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations:

None

PI Accessory Mutations:

None

PR Other Mutations:

I13V 98% cov=31,878 • K20R 89% cov=36,236 • E35D 82% cov=41,395 • M36I 98% cov=41,392 • R41K 99% cov=42,010 • R57K 93% cov=39,216 • H69K 94% cov=31,963 • L89M 96% cov=23,152

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

PR comments

Other

- K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for PI.	

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

M41L92% cov=18,917

D67DEE: 59%, D: 37% cov=32,775

K70R95% cov=21,305

M184V93% cov=12,875

K103N98% cov=21,928

P225H94% cov=19,982

V35T99% cov=18,555

T39K92% cov=18,430

V60I99% cov=20,572

K64KRE: 63%, R: 36% cov=20,836

W88A95% cov=22,827

K101Q96% cov=23,689

D121Y96% cov=22,256

K122E99% cov=22,230

D123G95% cov=20,640

I135V94% cov=19,665

A158T92% cov=34,605

K173S95% cov=12,696

Q174K95% cov=12,761

D177E97% cov=12,781

I178L91% cov=12,785

T200A97% cov=15,194

Q207A95% cov=14,355

R211S94% cov=17,261

F214L94% cov=18,089

K219G94% cov=18,962

L228R94% cov=20,704

V245K95% cov=24,548

D250E97% cov=25,739

I270INI: 61%, N: 38% cov=26,938

A272S94% cov=26,797

L282C96% cov=26,368

L283I95% cov=26,463

R284RKRE: 60%, R: 37% cov=29,584

T286A97% cov=28,984

I293V98% cov=32,121

E344D89% cov=67

P345Q94% cov=68

F346Y95% cov=67

R356K95% cov=63

R358K78% cov=59

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Intermediate Resistance

zidovudine (AZT)

Intermediate Resistance

emtricitabine (FTC)

High-Level Resistance

lamivudine (3TC)

High-Level Resistance

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

Intermediate Resistance

efavirenz (EFV)

High-Level Resistance

etravirine (ETR)

Susceptible

nevirapine (NVP)

High-Level Resistance

rilpivirine (RPV)

Susceptible

RT comments

NRTI

M41L

is a TAM that usually occurs with T215Y. In combination, **M41L** plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.

D67N

is a non-polymorphic TAM associated with low-level resistance to AZT. **D67G/E/S/T/H** are non-polymorphic NRTI-selected mutations that generally occur in viruses with multiple TAMs.

K70R

is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs.

M184V/I

cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). **M184V/I** are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

K103N

is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

P225H

is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of **P225H** and K103N synergistically reduces NVP, EFV and DOR susceptibility.

Other

K101Q

is a relatively non-polymorphic mutation that is weakly selected in persons receiving NVP and EFV. It is of uncertain phenotypic and clinical significance.

K219E/Q/N/R

are accessory TAMs that usually occur in combination with multiple other TAMs. K219W is an uncommon NRTI-selected mutation. **K219G** is an unusual mutation at this position.

Drug resistance mutation scores of NRTI:

Download CSV



Rule	ABC ↕	AZT ↕	FTC ↕	3TC ↕	TDF ↕
<u>M41L</u>	5	15	0	0	5
<u>D67DE</u>	5	15	0	0	5
<u>K70R</u>	5	30	0	0	5
<u>M184V</u>	15	-10	60	60	-10
Total	30	50	60	60	5

Drug resistance mutation scores of NNRTI:

Download CSV



Rule	DOR ↕	EFV ↕	ETR ↕	NVP ↕	RPV ↕
<u>K103N + P225H</u>	10	0	0	0	0
<u>P225H</u>	20	45	0	45	0
<u>K103N</u>	0	60	0	60	0
Total	30	105	0	105	0